Genprex to Present at the Spring 2021 Oncology Investor Conference on March 29
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, will present at the Spring 2021 Oncology Investor Conference from March 29 to April 2, 2021. President and CEO Rodney Varner will deliver a virtual company overview on March 29 at 2 p.m. EDT, focusing on innovative gene therapies for non-small cell lung cancer and diabetes. Genprex's lead candidate, REQORSA™, has received Fast Track Designation by the FDA for treating NSCLC in combination with osimertinib, aiming to improve treatment options for patients with limited alternatives.
- None.
- None.
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it will present at the Spring 2021 Oncology Investor Conference on March 29, 2021. Genprex’s President and Chief Executive Officer, Rodney Varner, will deliver a virtual company overview to investors, including its novel gene therapies for non-small cell lung cancer and diabetes.
Event: Oncology Investor Conference (Virtual)
Date: The conference will take place virtually March 29 - April 2, 2021
Presentation Date: Monday, March 29
Presentation Time: 2 p.m. Eastern Daylight Time
Registration Link: http://bit.ly/3qT3ztc
The Company invites investors to join the webcast presentation, and Mr. Varner will be available for one-on-one meetings with investors throughout the conference.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso®) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone.
For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes, regarding potential, current, regarding the Company’s future growth and financial status and regarding our commercial partnerships and intellectual property licenses. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of the effect of our product candidates, alone and in combination with other therapies, on cancer; the timing and success of our clinical trials and planned clinical trials of REQORSA™ immunogene therapy drug, alone and in combination with targeted therapies and/or immunotherapies, and whether our other potential product candidates, including GPX-002, our gene therapy in diabetes, advance into clinical trials; the success of our strategic partnerships, including those relating to manufacturing of our product candidates; the timing and success at all of obtaining any FDA approvals of REQORSA and our other potential product candidates including whether we receive necessary approvals to commence clinical trials or benefit from fast track or similar regulatory designations; costs associated with developing our product candidates, whether we identify and succeed in acquiring other technologies and whether patents will ever be issued under patent applications that are the subject of our license agreements or otherwise. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005294/en/
FAQ
When is Genprex's presentation at the Spring 2021 Oncology Investor Conference?
What key therapies will Genprex discuss at the conference?
What is the lead product candidate of Genprex?
What designation has the FDA granted to REQORSA?
How can investors register for the Oncology Investor Conference?
